开云app官网登录入口网页版-官方正版

#人体试验#

46篇内容 | 1701人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1513654, encodeId=a775151365485, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=Antimicrob Agents Chemother：首次人体试验证实NTM-1633可用于肉毒杆菌神经毒素导致的中毒, objectType=article, longId=726819, objectId=e8d4e2681941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d4e2681941, replyNumber=0, likeNumber=64, createdTime=2022-05-15, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d4e2681941, moduleTitle=Antimicrob Agents Chemother：首次人体试验证实NTM-1633可用于肉毒杆菌神经毒素导致的中毒, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e8d4e2681941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513653, encodeId=8865151365311, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=Cancers：突破！用超声根除肝癌，无转移、复发，正在人体试验, objectType=article, longId=724983, objectId=50bde2498305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50bde2498305, replyNumber=0, likeNumber=0, createdTime=2022-04-27, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50bde2498305, moduleTitle=Cancers：突破！用超声根除肝癌，无转移、复发，正在人体试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=50bde2498305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513651, encodeId=5f0b1513651a1, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, objectType=article, longId=724027, objectId=af24e240278a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af24e240278a, replyNumber=0, likeNumber=70, createdTime=2022-04-13, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af24e240278a, moduleTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=af24e240278a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513652, encodeId=72b0151365262, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=45, createdTime=2022-04-12, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513650, encodeId=f95815136502e, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=有效率99%！男性口服避孕药，安全且可逆，年底前开展人体试验, objectType=article, longId=301775, objectId=44d5301e753c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44d5301e753c, replyNumber=0, likeNumber=74, createdTime=2022-03-29, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44d5301e753c, moduleTitle=有效率99%！男性口服避孕药，安全且可逆，年底前开展人体试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=44d5301e753c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513649, encodeId=d2771513649b3, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=二甲双胍抗衰老人体试验，现在怎么样了？, objectType=article, longId=293832, objectId=9df629383221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df629383221, replyNumber=0, likeNumber=81, createdTime=2022-01-13, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df629383221, moduleTitle=二甲双胍抗衰老人体试验，现在怎么样了？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9df629383221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513648, encodeId=4c9e15136487e, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=全球首个口服小分子PD-(L)1人体试验数据披露, objectType=article, longId=220327, objectId=c2c022032e75, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2c022032e75, replyNumber=0, likeNumber=81, createdTime=2021-11-15, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2c022032e75, moduleTitle=全球首个口服小分子PD-(L)1人体试验数据披露, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c2c022032e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513647, encodeId=44fa151364ed8, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=澳新冠疫苗人体试验**阶段通过或4个月内面世, objectType=article, longId=198542, objectId=76e3198542c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76e3198542c4, replyNumber=0, likeNumber=81, createdTime=2020-08-03, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76e3198542c4, moduleTitle=澳新冠疫苗人体试验**阶段通过或4个月内面世, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=76e3198542c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513646, encodeId=c5da151364610, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=澳昆州大学新冠疫苗开始人体试验初步结果或9月发布, objectType=article, longId=197495, objectId=761f19e49502, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=761f19e49502, replyNumber=0, likeNumber=77, createdTime=2020-07-15, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=761f19e49502, moduleTitle=澳昆州大学新冠疫苗开始人体试验初步结果或9月发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=761f19e49502)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513645, encodeId=887c15136451d, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=Lancet：陈薇团队首次COVID-19疫苗人体试验结果：安全，可诱导快速免疫反应, objectType=article, longId=194793, objectId=4789194e93c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4789194e93c0, replyNumber=0, likeNumber=64, createdTime=2020-05-28, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4789194e93c0, moduleTitle=Lancet：陈薇团队首次COVID-19疫苗人体试验结果：安全，可诱导快速免疫反应, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4789194e93c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513644, encodeId=92c11513644c7, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=FDA指南简介：拓展队列用于首次人体试验加速抗肿瘤药物/生物制剂的开发, objectType=article, longId=193976, objectId=40ab1939e692, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ab1939e692, replyNumber=0, likeNumber=64, createdTime=2020-05-13, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ab1939e692, moduleTitle=FDA指南简介：拓展队列用于首次人体试验加速抗肿瘤药物/生物制剂的开发, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=40ab1939e692)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513643, encodeId=6fa41513643ea, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=辉瑞在美启动新冠疫苗人体试验，希望9月获紧急使用授权入市, objectType=article, longId=193599, objectId=355919359996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=355919359996, replyNumber=0, likeNumber=57, createdTime=2020-05-08, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=355919359996, moduleTitle=辉瑞在美启动新冠疫苗人体试验，希望9月获紧急使用授权入市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=355919359996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513642, encodeId=3309151364210, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=NAT MED：我国公布CRISPR人体试验结果, objectType=article, longId=193407, objectId=aeed19340e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeed19340e52, replyNumber=0, likeNumber=0, createdTime=2020-05-04, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeed19340e52, moduleTitle=NAT MED：我国公布CRISPR人体试验结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aeed19340e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513641, encodeId=5be515136410d, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=针对新型冠状病毒，目前已经有3种药物进入人体试验研究阶段, objectType=article, longId=188281, objectId=d8c118828178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8c118828178, replyNumber=0, likeNumber=64, createdTime=2020-02-19, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8c118828178, moduleTitle=针对新型冠状病毒，目前已经有3种药物进入人体试验研究阶段, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d8c118828178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513640, encodeId=14751513640b6, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=Sci Adc：人体试验已通过！长效避孕微针贴片，按压一分钟，有效一整月, objectType=article, longId=182873, objectId=c4f11828e31d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4f11828e31d, replyNumber=0, likeNumber=71, createdTime=2019-11-14, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4f11828e31d, moduleTitle=Sci Adc：人体试验已通过！长效避孕微针贴片，按压一分钟，有效一整月, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c4f11828e31d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513639, encodeId=35141513639a7, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=通用流感疫苗人体试验结果来了！有望更全面更长期预防, objectType=article, longId=181895, objectId=385618189597, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=385618189597, replyNumber=0, likeNumber=71, createdTime=2019-10-26, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=385618189597, moduleTitle=通用流感疫苗人体试验结果来了！有望更全面更长期预防, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=385618189597)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513638, encodeId=1c31151363830, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=Nature：用于脑癌治疗的新型个体化治疗性疫苗进行首次人体试验, objectType=article, longId=156685, objectId=eb5d1566853a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb5d1566853a, replyNumber=0, likeNumber=86, createdTime=2018-12-27, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb5d1566853a, moduleTitle=Nature：用于脑癌治疗的新型个体化治疗性疫苗进行首次人体试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb5d1566853a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513637, encodeId=92eb151363e35, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=Nature：全球首例移植干细胞治疗帕金森的人体试验启动, objectType=article, longId=153750, objectId=9d54153e50f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d54153e50f9, replyNumber=0, likeNumber=75, createdTime=2018-11-18, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d54153e50f9, moduleTitle=Nature：全球首例移植干细胞治疗帕金森的人体试验启动, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9d54153e50f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513636, encodeId=799315136364d, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=NEJM：人体试验疗效达100%！基因治疗突破成果, objectType=article, longId=135983, objectId=b0891359835a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0891359835a, replyNumber=0, likeNumber=65, createdTime=2018-04-22, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0891359835a, moduleTitle=NEJM：人体试验疗效达100%！基因治疗突破成果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b0891359835a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1513635, encodeId=243a151363538, content=<a href='/topic/show?id=c41924e0391' target=_blank style='color:#2F92EE;'>#人体试验#</a>, objectTitle=Aging Cell：分子J147成功逆转小鼠痴呆症，阿兹海默症人体试验引关注！, objectType=article, longId=126146, objectId=14531261468f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14531261468f, replyNumber=0, likeNumber=56, createdTime=2018-01-12, rootId=0, userName=ms5906905816781247, userId=d9ab10580029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14531261468f, moduleTitle=Aging Cell：分子J147成功逆转小鼠痴呆症，阿兹海默症人体试验引关注！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=14531261468f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

人体试验

2020-05-29

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

Antimicrob Agents Chemother：首次人体试验证实NTM-1633可用于肉毒杆菌神经毒素导致的中毒

2022-05-15

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

Cancers：突破！用超声根除肝癌，无转移、复发，正在人体试验

2022-04-27

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布

2022-04-13

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-04-12

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

有效率99%！男性口服避孕药，安全且可逆，年底前开展人体试验

2022-03-29

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

二甲双胍抗衰老人体试验，现在怎么样了？

2022-01-13

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

全球首个口服小分子PD-(L)1人体试验数据披露

2021-11-15

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

澳新冠疫苗人体试验**阶段通过或4个月内面世

2020-08-03

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

澳昆州大学新冠疫苗开始人体试验初步结果或9月发布

2020-07-15

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

Lancet：陈薇团队首次COVID-19疫苗人体试验结果：安全，可诱导快速免疫反应

2020-05-28

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

FDA指南简介：拓展队列用于首次人体试验加速抗肿瘤药物/生物制剂的开发

2020-05-13

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

辉瑞在美启动新冠疫苗人体试验，希望9月获紧急使用授权入市

2020-05-08

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

NAT MED：我国公布CRISPR人体试验结果

2020-05-04

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

针对新型冠状病毒，目前已经有3种药物进入人体试验研究阶段

2020-02-19

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

Sci Adc：人体试验已通过！长效避孕微针贴片，按压一分钟，有效一整月

2019-11-14

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

通用流感疫苗人体试验结果来了！有望更全面更长期预防

2019-10-26

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

Nature：用于脑癌治疗的新型个体化治疗性疫苗进行首次人体试验

2018-12-27

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

Nature：全球首例移植干细胞治疗帕金森的人体试验启动

2018-11-18

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

NEJM：人体试验疗效达100%！基因治疗突破成果

2018-04-22

ms5906905816781247 (审核中...)

前往app查看评论内容

#人体试验#

Aging Cell：分子J147成功逆转小鼠痴呆症，阿兹海默症人体试验引关注！

2018-01-12

科室
- - 订阅+
  - 更多科室
工具
服务